Disease Model Resources

White Paper: In Vivo Pre-Clinical Platforms to Study Post-COVID Lung Damage and Fibrosis

Aragen has accelerated several anti-IPF candidates to the clinic using its long-established bleomycin-induced pulmonary fibrosis model. In addition, we have also developed a lipopolysaccharide (LPS)-induced acute lung injury (ALI) model that is relevant for studying ARDS. Combined with extensive ex vivo readouts and translational lung function parameters, hundreds of studies have shown that these models are a robust and reliable platform for investigating drug candidates and may also be a timely solution for studying potential treatments for post-COVID fibrosis. This nine-page white paper details current challenges and how Aragen addresses them with various pulmonary fibrosis models. Complete the form below to download the White Paper.

Respiratory Disease Model Services

Aragen Bioscience has a portfolio of in vivo fibrosis models and the world-class expertise to support you during the development of your therapeutic. In hundreds of studies over the course of a decade, we have evaluated the efficacy of small molecules and biologic test compounds in a variety of models, ultimately resulting in multiple INDs for our clients. This flyer provides an overview of Aragen’s fibrosis model services. Download (no form). 

Technical Summary of Fibrosis Models

Technical summary of various fibrosis models offered by Aragen:

  • Lung fibrosis model in C57BL/6 mice
  • Silica-Induced Lung Fibrosis Model in mice
  • CCL4 induced liver fibrosis in mice
  • Nonalcoholic Steatohepatitis (NASH) model mice
  • Dermal fibrosis in a scleroderma mouse model

Complete the form below to download the Technical Summary.